Your browser is no longer supported. Please, upgrade your browser.
Settings
DEPO DepoMed Inc. daily Stock Chart
DEPO [NASD]
DepoMed Inc.
Index- P/E22.61 EPS (ttm)1.35 Insider Own0.40% Shs Outstand59.96M Perf Week-7.06%
Market Cap1.83B Forward P/E26.14 EPS next Y1.17 Insider Trans-2.04% Shs Float59.30M Perf Month42.26%
Income102.20M PEG0.75 EPS next Q0.00 Inst Own77.30% Short Float21.29% Perf Quarter31.26%
Sales346.00M P/S5.29 EPS this Y173.30% Inst Trans0.86% Short Ratio6.07 Perf Half Y61.88%
Book/sh6.05 P/B5.05 EPS next Y324.73% ROA18.40% Target Price30.08 Perf Year178.81%
Cash/sh1.02 P/C29.96 EPS next 5Y30.00% ROE41.20% 52W Range9.85 - 33.74 Perf YTD89.51%
Dividend- P/FCF273.22 EPS past 5Y46.60% ROI25.60% 52W High-9.51% Beta1.06
Dividend %- Quick Ratio9.80 Sales past 5Y46.60% Gross Margin95.80% 52W Low209.95% ATR1.25
Employees324 Current Ratio9.90 Sales Q/Q-57.90% Oper. Margin55.30% RSI (14)58.18 Volatility4.02% 3.70%
OptionableYes Debt/Eq0.68 EPS Q/Q-166.70% Profit Margin34.70% Rel Volume1.64 Prev Close31.87
ShortableYes LT Debt/Eq0.68 EarningsAug 06 AMC Payout0.00% Avg Volume2.08M Price30.53
Recom2.00 SMA202.58% SMA5023.42% SMA20047.46% Volume3,418,266 Change-4.20%
Jul-30-15Downgrade RBC Capital Mkts Outperform → Sector Perform $26 → $32
Jul-24-15Reiterated WallachBeth Hold $26 → $33
Jul-14-15Reiterated ROTH Capital Buy $28.50 → $33
Jun-11-15Initiated Morgan Stanley Equal-Weight $23
May-12-15Reiterated RBC Capital Mkts Outperform $29 → $26
Apr-22-15Initiated Piper Jaffray Overweight $37
Apr-06-15Reiterated ROTH Capital Buy $27 → $30
Mar-13-15Downgrade WallachBeth Buy → Hold $28 → $26
Jan-16-15Upgrade ROTH Capital Neutral → Buy $25
Jan-16-15Reiterated RBC Capital Mkts Outperform $20 → $22
Dec-10-14Initiated RBC Capital Mkts Outperform $20
Jul-10-14Initiated WallachBeth Buy $17
Feb-25-13Downgrade WallachBeth Buy → Hold $8 → $7
Jan-05-12Initiated JMP Securities Mkt Outperform $8
Sep-30-11Initiated Auriga Buy $10
Feb-18-10Downgrade Merriman Buy → Neutral
Oct-21-09Initiated Caris & Company Buy $9
Oct-12-09Reiterated Merriman Buy $11.50 → $7.50
Oct-05-09Initiated Merriman Buy
Jun-20-08Initiated Roth Capital Buy $5
Jul-30-15 04:43PM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:30AM  DEPO: DepoMed Reports Better Than Expected Product Sales
08:07AM  Depomed Rejected Horizon Pharma's Takeout Bid, But Still Trades As If M&A Is Happening
06:43AM  Ahead of the Bell: Depomed rejects Horizon offer
06:29AM  DepoMed downgraded by RBC Capital Mkts
Jul-29-15 10:08PM  Edited Transcript of DEPO earnings conference call or presentation 29-Jul-15 8:30pm GMT
05:52PM  Depomed reports 2Q loss
05:41PM  DepoMed Raises Guidance at The Wall Street Journal
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:26PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Amendments to Articles of Inc. or Byla
04:08PM  Depomed Rejects Horizon Pharmas Takeover Proposal as Inadequate at Bloomberg
04:04PM  Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance PR Newswire
04:03PM  Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc PR Newswire
08:00AM  Depomed to Report Second Quarter Fiscal Year 2015 Financial Results on Wednesday, July 29, 2015 PR Newswire
Jul-28-15 08:01AM  The real reasons for the pharma merger boom at Fortune
02:14AM  Mandel's Lone Pine Takes Stake in Growing Horizon Pharma
Jul-24-15 04:40PM  Dealpolitik: Depomed Makes the Best of Weak Takeover Defenses at The Wall Street Journal
Jul-21-15 06:32PM  Horizon Raises Bid for Specialty Pharma Company Depomed at TheStreet
03:48PM  Horizon raises offer for rival drugmaker Depomed at Financial Times
12:44PM  Horizon Boosts Depomed Bid to About $2 Billion at The Wall Street Journal
12:33PM  Horizon Pharma raises bid for Depomed to $33 per share
12:00PM  Horizon Pharma raises offer again to buy reluctant Depomed
11:30AM  Horizon Pharma Raises Hostile Depomed Bid to $1.98 Billion at Bloomberg
11:23AM  Depomed Confirms Receipt of Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc PR Newswire
10:50AM  Horizon Pharma Raises Bid For Depomed; Both Stocks Up at Investor's Business Daily
08:04AM  Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more at CNBC
07:12AM  Horizon Pharma raises offer for Depomed
Jul-20-15 06:50PM  Ethical-Drug Firms Horizon Pharma, Bristol-Myers Rally at Investor's Business Daily
11:57AM  Horizon Pharma Hits High As Q2 Sales Beat Street at Investor's Business Daily
11:20AM  Horizon Pharma Sees Record Quarter Ahead
09:47AM  Horizon Pharma CEO: Depotmed deal makes sense
Jul-16-15 09:33AM  Explainer: The Biotech raging bull at Financial Times
Jul-15-15 01:52PM  DepoMed Seen Holding Out for Higher Bid at Barrons.com
11:33AM  US biotech bull run sets scorching pace at Financial Times
Jul-14-15 03:37PM  Depomed adopts takeover defense after Horizon Pharma bid at MarketWatch
03:31PM  Depomed Adopts Takeover Defense at The Wall Street Journal
Jul-13-15 01:04PM  Depomed puts 'poison pill' plan in place
09:46AM  DepoMed (DEPO) Stock Climbs After Instituting Poison Pill Takeover Defense at TheStreet
09:34AM  Stocks to Watch: Apple, MarkWest Energy, Seagate, Depomed at The Wall Street Journal
07:56AM  Early movers: AAPL, DEPO, JAH, MPC, SNE & more at CNBC
06:04AM  DEPOMED INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financ
Jul-11-15 01:29AM  Charting the Market at Barrons.com
Jul-10-15 07:10PM  Fast-growing East Bay drug maker stares down hostile $3 billion bid at bizjournals.com +7.22%
12:40PM  Trending Now: DepoMed Inc.
Jul-09-15 07:11AM  Horizon's Hostile Bid for DepoMed Is Too Low at Motley Fool
Jul-08-15 06:30PM  Foreign Drugmakers Seen Posting Big Earnings Increases at Investor's Business Daily
04:53PM  Depomed Announces Decision in Inter Partes Review Proceeding against Purdue Pharma Confirming Patentability of All Challenged Claims PR Newswire
02:32PM  DepoMed (DEPO) Stock Declines After Rejecting Horizon Pharma's Latest $3 Billion Offer at TheStreet
02:04PM  Rate Hikes Won't Kill Pharma M&A Boomand These Stocks Could Be Next at Barrons.com
12:38AM  PRESS DIGEST- New York Times business news - July 8 Reuters
12:28AM  The Tax Inversion Wave Keeps Rolling at The Wall Street Journal
Jul-07-15 07:24PM  The Tax Inversion Wave Keeps Rolling at The Wall Street Journal +38.66%
06:20PM  Horizon Pharma Goes Hostile In Depomed Bid at Investor's Business Daily
05:00PM  Stocks Rebound Tuesday as Greece Drama Continues
03:19PM  Mid-Afternoon Market Update: A Schulman Slips After Q3 Results; Plug Power Shares Spike Higher
01:15PM  Horizon Pharma PLC -- Moody's: Horizon Pharma's Depomed offer is credit positive at Moody's
01:06PM  Mid-Day Market Update: Dow Tumbles 150 Points; Advanced Micro Devices Shares Slide On Nasty Guidance
12:25PM  DEPO: Horizon / Depomed Combination Makes Strategic Sense, But Offer Too Low
12:00PM  Stocks Lower Tuesday as Greece Drama Continues
11:43AM  Depomed rejects third buyout offer from Horizon at MarketWatch
11:39AM  Why Shares in DepoMed Inc. Are Charging 35% Higher at Motley Fool
11:25AM  Horizon Pharma Makes Hostile Bid to Acquire DepoMed
11:17AM  DepoMed (DEPO) Stock Spikes After Receiving Unsolicited $3 Billion Bid From Horizon Pharma at TheStreet
11:16AM  [$$] Horizon Pharma Offers to Buy Depomed for $1.75 Billion at The Wall Street Journal
11:06AM  Mid-Morning Market Update: Markets Drop; Horizon Pharma Proposes To Buy Depomed for $29.25/Share
11:05AM  Horizon Pharma makes hostile, $2.1B bid for Depomed
10:58AM  Irelands Horizon Pharma launches hostile, $3 billion bid for U.S. rival at Fortune
10:52AM  Cramer -- Investors Dislike Horizon Pharma Bid but Can Push Fitbit Higher at TheStreet
10:30AM  Depomed Confirms Receipt of Unsolicited Proposal from Horizon Pharma plc PR Newswire
10:03AM  Horizon Pharma Inc (HZNP)s $3 Billion Hostile Takeover Bid For Depomed Inc (DEPO) Has Investors Cautious: Good Chance To Buy Horizon? at Insider Monkey
09:35AM  Horizon Pharma proposes to buy Depomed for $1.75 billion at MarketWatch
09:23AM  Cramer's Mad Dash: Depomed & Fitbit
07:49AM  Early movers: MRK, TSLA, FIT, SHAK, NKE & more at CNBC
07:29AM  Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed at TheStreet
07:19AM  Horizon Pharma offers to buy Depomed in $3 billion deal
Jul-05-15 09:06AM  3 Moneymaking Biotech Stocks to Consider Buying at Motley Fool
Jun-26-15 08:03AM  Why This Small Cap Biotech Stock Is Becoming One of My Favorites at Motley Fool
Jun-17-15 04:05PM  Depomed Announces Change To Presentation Time At JMP Life Sciences Conference PR Newswire
Jun-10-15 06:02AM  DEPOMED INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibi
Jun-03-15 08:00AM  Depomed Announces ZipsorĀ® ANDA Litigation Settlement Providing for Exclusivity to March 2022 PR Newswire
Jun-01-15 04:29PM  O'Malley jabs Wall Street, presidential dynasties
May-29-15 11:20AM  Who's The Next Big Pharma Acquisition?
May-26-15 04:01PM  Depomed To Present At Healthcare Conferences In June PR Newswire
May-22-15 01:04PM  DEPOMED INC Financials
May-19-15 06:01AM  DEPOMED INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements
May-16-15 12:01AM  Best 100 Hedge Funds at Barrons.com
May-13-15 08:11PM  10-Q for Depomed, Inc. at Company Spotlight
04:14PM  DEPOMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04:01PM  Depomed To Present At Healthcare Conferences In May PR Newswire
03:27PM  Biotech provides a major plus for the stock market at MarketWatch
10:30AM  DEPO: Selloff Creates Great Opportunity In Depomed
May-12-15 03:58PM  Why the DepoMed Drop Is a Gross Overreaction at 24/7 Wall St. -16.30%
10:30AM  Depomed (DEPO) Stock Falls on Earnings Miss at TheStreet
May-11-15 08:41PM  5 Drug Stocks Moving On Earnings, Trial Data Late at Investor's Business Daily
08:27PM  Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers
05:25PM  After-hours buzz: Rackspace, Gap, Depomed & more at CNBC
04:43PM  Depomed reports 1Q loss
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:07PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Depomed Reports First Quarter 2015 Financial Results PR Newswire
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vargas Thadd MSenior VP, BDJun 12Sale20.705,000103,500138,153Jun 15 05:16 PM
STAPLE PETER DDirectorMay 12Option Exercise6.1810,00061,80060,000May 12 09:23 PM
Schoeneck James APresident and CEOMay 12Option Exercise6.6645,679304,13461,411May 12 09:21 PM
Vargas Thadd MSenior VP, BDApr 08Option Exercise6.1854,710338,010143,153Apr 09 04:50 PM
Vargas Thadd MSenior VP, BDJan 20Option Exercise5.0319,00095,57088,443Jan 22 06:28 PM
Schoeneck James APresident and CEODec 19Option Exercise8.3640,700340,25256,432Dec 22 09:14 AM
Gosling Matthew MSenior VP, General CounselDec 02Sale15.858,819139,80832,501Dec 03 05:36 PM
Schoeneck James APresident and CEODec 02Sale15.8536,727582,23352,930Dec 03 05:35 PM
Vargas Thadd MSenior VP, BDDec 02Sale15.858,247130,74069,443Dec 03 05:35 PM
Moretti August JChief Financial OfficerDec 02Sale15.855,33984,63922,564Dec 03 05:35 PM
STAPLE PETER DDirectorNov 25Option Exercise5.0410,00050,40050,000Nov 26 04:38 PM
Gosling Matthew MSenior VP, General CounselNov 19Option Exercise6.1771,000438,07088,211Nov 21 08:00 PM
Gosling Matthew MSenior VP, General CounselNov 19Sale15.3671,0001,090,34717,211Nov 21 08:00 PM
Schoeneck James APresident and CEOAug 01Option Exercise6.1130,000183,30042,898Aug 04 10:46 AM